Hepatitis C vaccine therapy (GlaxoSmithKline/ReiThera)

N/A

Report date: 2026/01/27 14:21:49

Base Information

Drug NameHepatitis C vaccine therapy (GlaxoSmithKline/ReiThera)
Drug Alias NamePerCvax丙型肝炎疫苗 - OkairosProCvaxAd6NSmutAdCh3NSmut +[6] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis CHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyIreland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of OxfordReithera Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcReithera SrlUniversity Of Oxford +[4] 
Active IndicationsN/A
Inactive IndicationsHepatitis CHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A